cbp-1 encodes a homolog of the mammalian transcriptional cofactors CBP (OMIM:600140) and p300 (E1A-BINDING PROTEIN, 300-KD; OMIM:602700) that have been shown to possess histone acetyltransferase activity, and which, when mutated, lead to Rubinstein-Taybi syndrome (OMIM:180849) and colorectal cancer (OMIM:114500); at least one splicing form of CBP-1 exhibits histone acetyltransferase (HAT) activity in vitro and has a glutamine/asparagine-rich domain; CBP-1 is required during embryogenesis for differentiation of all non-neuronal somatic cell types; CBP-1 is expressed very early in embryogenesis, suggesting that it may interact with maternally provided transcription factors, such as SKN-1, to specific developmental fates.
Enables RNA polymerase II-specific DNA-binding transcription factor binding activity; histone acetyltransferase activity; and lysine N-acetyltransferase activity, acting on acetyl phosphate as donor. Involved in several processes, including positive regulation of transcription by RNA polymerase II; regulation of distal tip cell migration; and spermatogenesis. Located in cytoplasm and nucleus. Expressed in alimentary system; distal tip cell; head; and tail. Human ortholog(s) of this gene implicated in several diseases, including Alzheimer's disease; Huntington's disease; Rubinstein-Taybi syndrome; and leukemia (multiple). Is an ortholog of human CREBBP (CREB binding protein).
Map position created from combination of previous interpolated map position (based on known location of sequence) and allele information. Therefore this is not a genetic map position based on recombination frequencies or genetic experiments. This was done on advice of the CGC.
CGC_data_submission
cep-1 has been used as an unapproved name for what is the CGC approved cbp-1 (R10E11.1). The real CGC approved cep-1 (F52B5.5) is a p53 homolog, whereas the approved cbp-1 is a p300 homolog